Croma-Pharma
Patrick Reichl has a background in genetics and biology, with a focus on toxicological risk assessments and nonclinical development. Patrick has held positions as a Research Scientist and Senior Scientific Professional at various companies including Croma Pharma and Shire. Patrick is currently serving as the Toxicology Lead for Nonclinical Development & CMC at Croma Pharma, where Patrick oversees non-clinical strategies for regulatory submissions of Class III medical devices. Their expertise lies in scientific evaluation of projects and toxicological risk assessments for pharmaceuticals, materials, and impurities. Patrick holds a PhD in Biology from the University of Vienna, along with a MSc in Toxicology and MSc in Genetics from other institutions.
This person is not in the org chart
This person is not in any offices
Croma-Pharma
4 followers
Croma is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads and biostimulators complemented by its own skincare brand. Founded in 1976 by a pharmacist couple, Croma-Pharma GmbH is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US, Canada, China, Australia and New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.